Association of Fibrate use with clinical expression of hypertrophic cardiomyopathy.

ABSTRACT:

Aims

An association between obesity, metabolic abnormalities and clinical hypertrophic cardiomyopathy (HCM) expression has been reported. We investigated whether managing dyslipidaemia with fibrates could affect the clinical expression of HCM.

Methods

We screened patients who used fibrates between 2010 and 2017 from a nationwide database. After excluding patients with a history of HCM, we identified fibrate-user group (n = 412 823). We then constructed a 1:1 matched cohort of fibrate-naïve participants (n = 412 823). After a 1 year lag period, we identified the incident HCM cases for the following 5 years.

Results

During a median follow-up period of 3.96 years, we identified 454 incident clinical HCM cases. After adjusting for covariates, fibrate use was associated wi

SUBMITTER: Park CS 

PROVIDER: S-EPMC11631236 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature